{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:36:23Z","timestamp":1784039783117,"version":"3.55.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015918","name":"Dipartimento di Scienze Mediche, Universit\u00e0 degli Studi di Torino","doi-asserted-by":"publisher","award":["TGT Study"],"award-info":[{"award-number":["TGT Study"]}],"id":[{"id":"10.13039\/100015918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007364","name":"Fondazione CRT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Oncohematological disorders are heterogeneous conditions that present significant challenges in management prior to transplantation. Data about rejection risk, disease recurrence, eligibility criteria, and requested remission time before kidney transplant (KT) are still lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All KTRs between January 1, 2000, and March 31, 2023 (n = 2871) were analyzed. All patients with an oncohematological disease (hematological cohort, including plasma cell dyscrasias [PCDs], acute leukemia, high-grade lymphoma\/post-transplant lymphoproliferative disorders [PTLDs], myeloproliferative neoplasms [MPNs], myelodysplastic\/myeloproliferative neoplasms [MDS\/MPNs], and genetic\/AA amyloidosis) were matched 1:2 by age at transplant, gender, type of dialysis, and eGFR at transplant with KTRs without a history of hematological disease (control cohort). Primary endpoints were death-censored graft survival and the risk of rejection. Secondary endpoints included the risk of hematological disease recurrence and infection, patient survival rates, and graft function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty out of 2871 patients (1.04%) receiving 31\/3019 KTs have a pre-existing oncohematological disease (hematological cohort): 7\/30 (23.3%) PCDs, 4\/30 (13.3%) acute leukemia, 8\/30 (26.7%) high-grade lymphomas\/PTLDs, 4\/30 (13.3%) MPNs, 2\/30 (6.7%) MDS\/MPNs, and 5\/30 (16.7%) AA\/familiar amyloidosis. Patients were transplanted at a median time of 5 (PCDs), 11.8 (acute leukemia), 12.3 (high-grade lymphomas\/PTLDs), 8.5 (MPNs), 3.6 (MDS\/MPNs), and 3.5 years (amyloidosis) after achieving disease remission (or stable disease in smoldering myeloma, MPNs, and MDS\/MPNs). Comparing hematological and control cohorts, no differences were observed in patient and graft survival or post-transplant complications, including acute rejections. Results are superimposable also without considering the three patients who underwent living KTs from the same donor as the bone marrow transplant. Hematological disease relapses were observed in 2\/30 (6.6%), including a light-chain deposition and a Castleman disease, both of which were successfully treated with chemotherapy without allograft dysfunction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Favorable long-term transplant and clinical outcomes were achieved in patients with various pre-existing oncological and hematological disorders. These patients should not be denied KT after a well-documented stable disease. In this context, a multidisciplinary approach is crucial for establishing standardized pre- and post-transplant monitoring protocols and achieving optimal graft and patient outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1629521","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:32Z","timestamp":1754453552000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Pre-existing oncohematological disease in kidney transplant recipients: impact on graft survival, acute rejection, and long-term clinical outcomes"],"prefix":"10.3389","volume":"16","author":[{"given":"Alberto","family":"Mella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Clari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Deiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Giraudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Giovinazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Dolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lavacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Manzione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Fop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Allesina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Tarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Biancone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1503\/cmaj.1041588","article-title":"Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation","volume":"173","author":"Knoll","year":"2005","journal-title":"CMAJ"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12068","article-title":"KHA-cari Guideline: Recipient assessment for transplantation","volume":"18","author":"Campbell","year":"2013","journal-title":"Nephrology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1034\/J.1600-6143.2001.0010S2001.X","article-title":"The evaluation of the renal transplant candidates: clinical practice guidelines","volume":"1","author":"Kasiske","year":"2001","journal-title":"Am J Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu216","article-title":"European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care","volume":"30","author":"Abramowicz","year":"2015","journal-title":"Nephrol Dialysis Transplant"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa105","article-title":"Monoclonal gammopathy of undetermined significance coexisting in patients undergoing kidney transplantation does not adversely influence post-graft clinical outcome","volume":"14","author":"Clari","year":"2021","journal-title":"Clin Kidney J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000493","article-title":"Diagnostic approach to myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms","volume":"32","author":"Prakash","year":"2025","journal-title":"Adv Anat Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2010-05-282632","article-title":"Incidence of hematologic Malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-2141.2004.05207.x","article-title":"A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK","volume":"127","author":"Phekoo","year":"2004","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9206-17","article-title":"Nationwide survey of 741 patients with systemic amyloid light-chain amyloidosis in Japan","volume":"57","author":"Shimazaki","year":"2018","journal-title":"Internal Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr578","article-title":"Racial disparities in Hodgkin\u2019s lymphoma: A comprehensive population-based analysis","volume":"23","author":"Evens","year":"2012","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000544","article-title":"Current opinions in nephrology and hypertension: Kidney transplantation in patients with plasma cell dyscrasias","volume":"28","author":"Lum","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12659","article-title":"Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder","volume":"30","author":"Rouphael","year":"2016","journal-title":"Clin Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01543.x","article-title":"Retransplantation after post-transplant lymphoproliferative disorders: An OPTN\/UNOS database analysis","volume":"6","author":"Johnson","year":"2006","journal-title":"Am J Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.09.020","article-title":"Long-term outcome of renal transplantation in light-chain deposition disease","volume":"43","author":"Leung","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.04.021","article-title":"Recurrent light chain proximal tubulopathy in a kidney allograft","volume":"68","author":"Angioi","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2012.01674.x","article-title":"A case of recurrent light chain deposition disease after living-related renal transplantation - detailed process of the recurrence","volume":"26","author":"Horike","year":"2012","journal-title":"Clin Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2006.00437.x","article-title":"Recurrence of light chain deposit disease after renal allograft transplantation: Potential role of rituximab","volume":"20","author":"Kuypers","year":"2007","journal-title":"Transplant Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh822","article-title":"Recurrent light and heavy chain deposition disease after renal transplantation","volume":"20","author":"Alchi","year":"2005","journal-title":"Nephrology Dialysis Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000046254","article-title":"Recurrence of light chain nephropathy in a renal allograft : A case report and review of the literature","volume":"21","author":"Short","year":"2001","journal-title":"Am J Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12099","article-title":"Successful renal transplantation for end-stage renal insufficiency developed in a patient with Castleman\u2019s disease","volume":"26","author":"Murakami","year":"2013","journal-title":"Transplant Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4314\/ajnt.v4i1.63153","article-title":"Case report: castleman\u2019s disease in a kidney failure patient diagnosed incidentally during transplantation","volume":"4","author":"Yousif","year":"2011","journal-title":"Arab J Nephrol Transplant"},{"key":"B27","article-title":"Skull mass as the first manifestation of recurrent multiple myeloma in a renal transplant patient","volume":"62","author":"Taheri","year":"2012","journal-title":"J Pak Med Assoc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2007.02.015","article-title":"Recurrent multiple myeloma following renal transplantation: A case report","volume":"39","author":"Taheri","year":"2007","journal-title":"Transplant Proc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1053\/kd.2000.6429","article-title":"Heavy chain deposition disease: recurrence in a renal transplant and report of IgG(2) subtype","volume":"35","author":"Herzenberg","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000341760","article-title":"Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias","volume":"120","author":"Bansal","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e14541","DOI":"10.1111\/ctr.14541","article-title":"Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series","volume":"36","author":"Dinh","year":"2022","journal-title":"Clin Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.111","article-title":"Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: On the verge of an explosion","volume":"48","author":"Nayak","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3727\/096368915X688560","article-title":"Hematopoietic cell and renal transplantation in plasma cell dyscrasia patients","volume":"25","author":"Baraldi","year":"2016","journal-title":"Cell Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl403","article-title":"A case of successful double sequential bone marrow and kidney transplantations in a patient with multiple myeloma","volume":"21","author":"Khoriaty","year":"2006","journal-title":"Nephrol Dialysis Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.10.005","article-title":"Successful treatment of renal failure caused by multiple myeloma with HLA-identical living kidney and bone marrow transplantation: A case report","volume":"45","author":"Wagner","year":"2013","journal-title":"Transplant Proc"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31820a3068","article-title":"Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease","volume":"91","author":"Spitzer","year":"2011","journal-title":"Transplantation"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03187.x","article-title":"Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: A retrospective, multicenter study of the EBMT","volume":"10","author":"Koenecke","year":"2010","journal-title":"Am J Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000852","article-title":"Ten year follow-up for a patient postmatched unrelated donor bone marrow transplant followed by same donor kidney transplant: normal renal function without immunosuppression","volume":"99","author":"Younge","year":"2015","journal-title":"Transplantation"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1007\/s004670050297","article-title":"Retransplantation after post-transplant lymphoproliferative disease","volume":"11","author":"Demircin","year":"1997","journal-title":"Pediatr Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000072015.08302.E9","article-title":"Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: Duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation","volume":"76","author":"Birkeland","year":"2003","journal-title":"Transplantation"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00562.x","article-title":"Successful renal retransplantation after post-transplant lymphoproliferative disease","volume":"4","author":"Karras","year":"2004","journal-title":"Am J Transplant"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2024.03.004","article-title":"A case report of kidney transplantation in a patient with pre-existing chronic myeloid leukemia: the role of achieving molecular response and treatment-free remission","volume":"56","author":"Pinlac","year":"2024","journal-title":"Transplant Proc"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16194","article-title":"Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib","volume":"21","author":"Thiem","year":"2021","journal-title":"Am J Transplant"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2023.03.058","article-title":"A case report of successful kidney transplantation in a patient with chronic myelogenous leukemia (CML) who has been in remission for 15 years on imatinib","volume":"55","author":"Tokumoto","year":"2023","journal-title":"Transplant Proc"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2019.06.001","article-title":"Impact of pre-transplant Malignancy on outcomes after kidney transplantation: united network for organ sharing database analysis","volume":"229","author":"Livingston-Rosanoff","year":"2019","journal-title":"J Am Coll Surgeons"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-024-01888-w","article-title":"Kidney transplants from elderly donors: what we have learned 20 years after the Crystal City consensus criteria meeting","volume":"37","author":"Mella","year":"2024","journal-title":"J Nephrol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.3390\/jcm10112349","article-title":"Tumor recurrence and graft survival in renal transplant recipients with a history of pretransplant Malignancy: A matched pair analysis","volume":"10","author":"Becker","year":"2021","journal-title":"J Clin Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac239","article-title":"Malignancies in adult kidney transplant candidates and recipients: Current status","volume":"38","author":"Serkies","year":"2023","journal-title":"Nephrol Dialysis Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1629521\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:33Z","timestamp":1754453553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1629521\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2025.1629521"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1629521","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1629521"}}